The short version
9 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
brivaracetam · BRIVARACETAM 75 mg/1 · Tablet, Film Coated · Oral · AvKARE
NDC 73190-0076-60 · 60 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →
9 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Matched to CMS's representative package for this drug (NDC 50474-0670-66) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
sole-source market · price up 3% YoY
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Aurobindo Pharma Limited | BRIVARACETAM 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | BRIVARACETAM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | BRIVARACETAM 75 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | BRIVARACETAM 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | BRIVARACETAM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | BRIVARACETAM 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | BRIVARACETAM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | BRIVARACETAM 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | BRIVARACETAM 75 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | BRIVARACETAM 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | BRIVARACETAM 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| SolarisPharmaCorporation | BRIVARACETAM 75 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| SolarisPharmaCorporation | BRIVARACETAM 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| SolarisPharmaCorporation | BRIVARACETAM 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| SolarisPharmaCorporation | BRIVARACETAM 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| SolarisPharmaCorporation | BRIVARACETAM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| UCB Pharma S.A. | BRIVARACETAM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| UCB Pharma S.A. | BRIVARACETAM 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| UCB Pharma S.A. | BRIVARACETAM 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| UCB Pharma S.A. | BRIVARACETAM 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| UCB Pharma S.A. | BRIVARACETAM 75 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| UCB, Inc. | BRIVARACETAM 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| UCB, Inc. | BRIVARACETAM 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| UCB, Inc. | BRIVARACETAM 75 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| UCB, Inc. | BRIVARACETAM 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| UCB, Inc. | BRIVARACETAM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | BRIVARACETAM 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | BRIVARACETAM 75 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | BRIVARACETAM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | BRIVARACETAM 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | BRIVARACETAM 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | BRIVARACETAM 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | BRIVARACETAM 75 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | BRIVARACETAM 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | BRIVARACETAM 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals USA Inc. | BRIVARACETAM 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | BRIVARACETAM 10 mg/1 | Jul 18, 2026 | Aug 29, 2026 |
| Aurobindo Pharma Limited | BRIVARACETAM 75 mg/1 | Jul 18, 2026 | Aug 29, 2026 |
| Aurobindo Pharma Limited | BRIVARACETAM 25 mg/1 | Jul 18, 2026 | Aug 29, 2026 |
| ScieGen Pharmaceuticals, Inc. | BRIVARACETAM 25 mg/1 | Jul 24, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "brivaracetam — NDC 73190-0076-60," retrieved September 3, 2026, https://drugdashboards.com/drug/73190007660.
Free to cite with attribution — see how the data is put together.